Related Experiment Video
Updated: May 27, 2026
07:30
Robot-Assisted Kidney Transplantation
Published on: July 19, 2021
[Perspectives in pediatric renal transplantation]
Gwenaelle Roussey-Kesler1, Stéphane Decramer
1Clinique Médicale Pédiatrique, Hôpital Mère Enfant, 7 Quai Moncousu, 44093 Nantes cedex, France. gwenaelle.roussey@chu-nantes.fr
Nephrologie & Therapeutique
|November 29, 2011
Summary
New immunosuppressive drugs, including Belatacept, are being explored for kidney transplant patients to prevent toxicities. Future strategies may involve personalized regimens and vaccines against Epstein-Barr virus (EBV) and cytomegalovirus (CMV).
Area of Science:
- Immunology
- Nephrology
- Transplantation medicine
Context:
- Adult renal transplant recipients often receive new immunosuppressive drugs to mitigate toxicities like nephrotoxicity and cardiovascular complications.
- Belatacept shows promise, with ongoing validation for pediatric use, particularly in Epstein-Barr virus (EBV)-positive patients.
- Rituximab, bortezomide, and eculizumab are under investigation for desensitization protocols and treating humoral rejections.
Purpose:
- To review current and emerging immunosuppressive strategies in renal transplantation.
- To highlight the potential of Belatacept in pediatric recipients.
- To discuss future directions in personalized immunosuppression and infection prevention.
Summary:
- Belatacept demonstrates positive outcomes in adult renal transplantation, with its use in pediatric patients, especially EBV-positive ones, requiring further validation.
- Other agents like rituximab, bortezomide, and eculizumab are being evaluated for desensitization and humoral rejection treatment.
- Future immunosuppressive regimens may be tailored based on genetic polymorphisms and biomarkers of immune status and alloreactivity.
- Development of vaccines against EBV and CMV could prevent post-transplant infections.
Impact:
- Informs clinicians about advanced immunosuppressive options and future personalized approaches in renal transplantation.
- Highlights the need for further research into Belatacept's efficacy and safety in pediatric populations.
- Emphasizes the potential of biomarker-driven and vaccine-based strategies to improve transplant outcomes and reduce infection risks.
Related Concept Videos
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
01:16Kidney Transplant III: Nursing Management
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...